Cargando…

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator

BACKGROUND: To assess the health-related quality of life (HRQoL) of Taiwan patients with different stages of chronic obstructive pulmonary disease (COPD) and using different combination therapies and to explore the factors affecting HRQoL in these patients. METHODS: This cross-sectional study includ...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Pik-Qi, Sheu, Chau-Chyun, Tsai, Jong-Rung, Chang, Hsu-Liang, Lee, Li-Yao, Chen, Chung-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994661/
https://www.ncbi.nlm.nih.gov/pubmed/35411135
http://dx.doi.org/10.2147/PPA.S355023
_version_ 1784684152853889024
author Chin, Pik-Qi
Sheu, Chau-Chyun
Tsai, Jong-Rung
Chang, Hsu-Liang
Lee, Li-Yao
Chen, Chung-Yu
author_facet Chin, Pik-Qi
Sheu, Chau-Chyun
Tsai, Jong-Rung
Chang, Hsu-Liang
Lee, Li-Yao
Chen, Chung-Yu
author_sort Chin, Pik-Qi
collection PubMed
description BACKGROUND: To assess the health-related quality of life (HRQoL) of Taiwan patients with different stages of chronic obstructive pulmonary disease (COPD) and using different combination therapies and to explore the factors affecting HRQoL in these patients. METHODS: This cross-sectional study included outpatient participants aged 35 years old and older who were receiving long-acting bronchodilator treatment in one of two hospitals in Southern Taiwan. Participants were categorized according to their Global Initiative for Obstructive Lung Disease (GOLD) classification as either their COPD group, based on symptoms and exacerbation risk, or their COPD stage, based on spirometry results. Patients’ HRQoL was assessed using the St. George’s Respiratory Questionnaire score (SGRQ), World Health Organization Quality of Life Quality of Life-BREF (WHOQOL-BREF), and EQ-5D-5L. The total scores of the SGRQ, WHOQOL-BREF, EQ-5D utility index, and EQ-VAS were presented as mean ± standard deviation (SD) among different combination treatments. Univariate and multivariate analyses were used to explore the association of patients’ baseline characteristics and environmental factors with HRQoL. RESULTS: A total of 218 patients were enrolled in the study. The distribution of patients using GOLD group classification were as follows: 73.39% in group A, 20.19% group B, 1.83% group C and 4.59% group D. Triple therapy patients mostly showed a lower quality of life than other combination therapies, regardless of the GOLD classification system. However, only the SGRQ scores of GOLD groups A and B were significantly different when using different drug combinations (p-value = 0.0072 and 0.0430, respectively). The COPD assessment test (CAT) score, a questionnaire to assess impact of COPD on health status, was found to be associated with all the questionnaires. CONCLUSION: The HRQoL is impaired in patients with COPD, and it deteriorates with an increase of severity. The CAT was the strongest predictor of HRQoL.
format Online
Article
Text
id pubmed-8994661
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-89946612022-04-10 Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator Chin, Pik-Qi Sheu, Chau-Chyun Tsai, Jong-Rung Chang, Hsu-Liang Lee, Li-Yao Chen, Chung-Yu Patient Prefer Adherence Original Research BACKGROUND: To assess the health-related quality of life (HRQoL) of Taiwan patients with different stages of chronic obstructive pulmonary disease (COPD) and using different combination therapies and to explore the factors affecting HRQoL in these patients. METHODS: This cross-sectional study included outpatient participants aged 35 years old and older who were receiving long-acting bronchodilator treatment in one of two hospitals in Southern Taiwan. Participants were categorized according to their Global Initiative for Obstructive Lung Disease (GOLD) classification as either their COPD group, based on symptoms and exacerbation risk, or their COPD stage, based on spirometry results. Patients’ HRQoL was assessed using the St. George’s Respiratory Questionnaire score (SGRQ), World Health Organization Quality of Life Quality of Life-BREF (WHOQOL-BREF), and EQ-5D-5L. The total scores of the SGRQ, WHOQOL-BREF, EQ-5D utility index, and EQ-VAS were presented as mean ± standard deviation (SD) among different combination treatments. Univariate and multivariate analyses were used to explore the association of patients’ baseline characteristics and environmental factors with HRQoL. RESULTS: A total of 218 patients were enrolled in the study. The distribution of patients using GOLD group classification were as follows: 73.39% in group A, 20.19% group B, 1.83% group C and 4.59% group D. Triple therapy patients mostly showed a lower quality of life than other combination therapies, regardless of the GOLD classification system. However, only the SGRQ scores of GOLD groups A and B were significantly different when using different drug combinations (p-value = 0.0072 and 0.0430, respectively). The COPD assessment test (CAT) score, a questionnaire to assess impact of COPD on health status, was found to be associated with all the questionnaires. CONCLUSION: The HRQoL is impaired in patients with COPD, and it deteriorates with an increase of severity. The CAT was the strongest predictor of HRQoL. Dove 2022-04-05 /pmc/articles/PMC8994661/ /pubmed/35411135 http://dx.doi.org/10.2147/PPA.S355023 Text en © 2022 Chin et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chin, Pik-Qi
Sheu, Chau-Chyun
Tsai, Jong-Rung
Chang, Hsu-Liang
Lee, Li-Yao
Chen, Chung-Yu
Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
title Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
title_full Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
title_fullStr Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
title_full_unstemmed Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
title_short Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
title_sort establishing quality of life in southern taiwan copd patients using long-acting bronchodilator
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994661/
https://www.ncbi.nlm.nih.gov/pubmed/35411135
http://dx.doi.org/10.2147/PPA.S355023
work_keys_str_mv AT chinpikqi establishingqualityoflifeinsoutherntaiwancopdpatientsusinglongactingbronchodilator
AT sheuchauchyun establishingqualityoflifeinsoutherntaiwancopdpatientsusinglongactingbronchodilator
AT tsaijongrung establishingqualityoflifeinsoutherntaiwancopdpatientsusinglongactingbronchodilator
AT changhsuliang establishingqualityoflifeinsoutherntaiwancopdpatientsusinglongactingbronchodilator
AT leeliyao establishingqualityoflifeinsoutherntaiwancopdpatientsusinglongactingbronchodilator
AT chenchungyu establishingqualityoflifeinsoutherntaiwancopdpatientsusinglongactingbronchodilator